Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.45
THRX's Cash to Debt is ranked higher than
55% of the 919 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. THRX: 0.45 )
THRX' s 10-Year Cash to Debt Range
Min: 0.45   Max: No Debt
Current: 0.45

Equity to Asset -0.31
THRX's Equity to Asset is ranked lower than
51% of the 768 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. THRX: -0.31 )
THRX' s 10-Year Equity to Asset Range
Min: -1.04   Max: 0.67
Current: -0.31

-1.04
0.67
F-Score: 1
Z-Score: -2.47
M-Score: -0.91
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -5327.31
THRX's Operating margin (%) is ranked higher than
51% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. THRX: -5327.31 )
THRX' s 10-Year Operating margin (%) Range
Min: -53258.33   Max: -9.58
Current: -5327.31

-53258.33
-9.58
Net-margin (%) -7161.99
THRX's Net-margin (%) is ranked higher than
51% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -69.75 vs. THRX: -7161.99 )
THRX' s 10-Year Net-margin (%) Range
Min: -50786.54   Max: -13.66
Current: -7161.99

-50786.54
-13.66
ROE (%) -144.32
THRX's ROE (%) is ranked higher than
54% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -28.10 vs. THRX: -144.32 )
THRX' s 10-Year ROE (%) Range
Min: -270.22   Max: -54.55
Current: -144.32

-270.22
-54.55
ROA (%) -36.19
THRX's ROA (%) is ranked higher than
66% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -21.69 vs. THRX: -36.19 )
THRX' s 10-Year ROA (%) Range
Min: -82.22   Max: -5.91
Current: -36.19

-82.22
-5.91
ROC (Joel Greenblatt) (%) -2190.18
THRX's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 909 Companies
in the Global Biotechnology industry.

( Industry Median: -217.20 vs. THRX: -2190.18 )
THRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1741.57   Max: -133.15
Current: -2190.18

-1741.57
-133.15
Revenue Growth (%) -47.20
THRX's Revenue Growth (%) is ranked higher than
59% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. THRX: -47.20 )
THRX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 125.7
Current: -47.2

0
125.7
EBITDA Growth (%) 14.50
THRX's EBITDA Growth (%) is ranked higher than
89% of the 619 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. THRX: 14.50 )
THRX' s 10-Year EBITDA Growth (%) Range
Min: -63.2   Max: 14.5
Current: 14.5

-63.2
14.5
EPS Growth (%) 12.90
THRX's EPS Growth (%) is ranked higher than
87% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. THRX: 12.90 )
THRX' s 10-Year EPS Growth (%) Range
Min: -47.1   Max: 12.9
Current: 12.9

-47.1
12.9
» THRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

THRX Guru Trades in Q3 2013

Jeremy Grantham 54,440 sh (+161.73%)
Seth Klarman 18,510,371 sh (+11.92%)
Jean-Marie Eveillard 1,223,220 sh (+10.24%)
Jim Simons 458,320 sh (-22.88%)
Steven Cohen 23,500 sh (-53%)
» More
Q4 2013

THRX Guru Trades in Q4 2013

Louis Moore Bacon 50,000 sh (New)
Steven Cohen 35,120 sh (+49.45%)
Jeremy Grantham 72,694 sh (+33.53%)
Jean-Marie Eveillard 1,509,404 sh (+23.4%)
Seth Klarman 20,144,301 sh (+8.83%)
Jim Simons 493,020 sh (+7.57%)
» More
Q1 2014

THRX Guru Trades in Q1 2014

Chuck Royce 22,900 sh (New)
Jean-Marie Eveillard 1,595,520 sh (+5.71%)
Seth Klarman 20,705,801 sh (+2.79%)
Louis Moore Bacon Sold Out
Steven Cohen Sold Out
Jeremy Grantham 32,200 sh (-55.7%)
Jim Simons 136,334 sh (-72.35%)
» More
Q2 2014

THRX Guru Trades in Q2 2014

Richard Perry 1,517,208 sh (New)
Jean-Marie Eveillard 1,595,520 sh (unchged)
Jim Simons Sold Out
Jeremy Grantham Sold Out
Seth Klarman 20,395,056 sh (-1.5%)
Chuck Royce 4,300 sh (-81.22%)
» More
» Details

Insider Trades

Latest Guru Trades with THRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Perry 2014-06-30 New Buy1.2%$21.154 - $30.1 $ 18.59-22%1517208
Seth Klarman 2014-06-30 Reduce -1.5%0.23%$21.154 - $30.1 $ 18.59-22%20395056
Seth Klarman 2014-03-31 Add 2.79%0.42%$24.31 - $32.63 $ 18.59-37%20705801
Seth Klarman 2013-12-31 Add 8.83%1.65%$27.19 - $32.81 $ 18.59-36%20144301
Jean-Marie Eveillard 2013-12-31 Add 23.4%0.03%$27.19 - $32.81 $ 18.59-36%1509404
Seth Klarman 2013-09-30 Add 11.92%2.3%$28.86 - $34.36 $ 18.59-40%18510371
Seth Klarman 2013-06-30 Add 22.02%2.85%$18.15 - $33.74 $ 18.59-31%16538977
Jean-Marie Eveillard 2013-06-30 Add 139.14%0.08%$18.15 - $33.74 $ 18.59-31%1109620
Jean-Marie Eveillard 2012-06-30 Add 24.23%0.01%$14.11 - $19.04 $ 18.5911%509710
Seth Klarman 2012-03-31 Add 2.3%0.22%$13.21 - $16.28 $ 18.5934%14553800
Jean-Marie Eveillard 2012-03-31 Add 25.59%0.01%$13.21 - $16.28 $ 18.5934%410310
Julian Robertson 2011-09-30 Sold Out 1.2512%$14.05 - $20.04 $ 18.5911%0
Seth Klarman 2011-09-30 Add 9.76%0.84%$14.05 - $20.04 $ 18.5911%14225961
Jean-Marie Eveillard 2011-06-30 Reduce -33.79%0.02%$17.07 - $23.13 $ 18.59-7%326710
John Griffin 2011-06-30 Sold Out $17.07 - $23.13 $ 18.59-7%0
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Theravance Inc

Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold
Renowned value investor Seth Klarman just reported his third quarter portfolio. He runs a very concentrated portfolio, with top two positions account for more than 50% of the stocks he owns. Seth Klarman buys Micron Technology, Inc., Theravance, Inc., PBF Energy Inc, Idenix Pharmaceuticals, Inc., Chipmos Technologies Bermuda Ltd., Idenix Pharmaceuticals, Inc., sells BP PLC, American International Group Inc, Yamana Gold Inc, Central Pacific Financial Corporation, Kinross Gold Corporation, Ituran Location and Control, Ltd., Alliance One International Inc, Pretium Resources, Inc. during the 3-months ended 09/30/2013, according to the most recent filings of his investment company, The Baupost Group. Read more...

Ratios

vs
industry
vs
history
P/S 619.67
THRX's P/S is ranked higher than
63% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 20.23 vs. THRX: 619.67 )
THRX' s 10-Year P/S Range
Min: 8.87   Max: 1013.33
Current: 619.67

8.87
1013.33
EV-to-EBIT -11.82
THRX's EV-to-EBIT is ranked higher than
61% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. THRX: -11.82 )
THRX' s 10-Year EV-to-EBIT Range
Min: 16.8   Max: 22.1
Current: -11.82

16.8
22.1
Current Ratio 7.06
THRX's Current Ratio is ranked higher than
85% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.97 vs. THRX: 7.06 )
THRX' s 10-Year Current Ratio Range
Min: 2.41   Max: 16.1
Current: 7.06

2.41
16.1
Quick Ratio 7.06
THRX's Quick Ratio is ranked higher than
86% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 3.81 vs. THRX: 7.06 )
THRX' s 10-Year Quick Ratio Range
Min: 2.41   Max: 15.83
Current: 7.06

2.41
15.83

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.34
THRX's Dividend Yield is ranked higher than
61% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. THRX: 1.34 )
THRX' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 1.34

Yield on cost (5-Year) 1.30
THRX's Yield on cost (5-Year) is ranked higher than
58% of the 180 Companies
in the Global Biotechnology industry.

( Industry Median: 1.18 vs. THRX: 1.30 )
THRX' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 1.3

Share Buyback Rate -12.40
THRX's Share Buyback Rate is ranked higher than
74% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. THRX: -12.40 )
THRX' s 10-Year Share Buyback Rate Range
Min: -2.2   Max: -105.4
Current: -12.4

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 10.56
THRX's Price/Median PS Value is ranked higher than
65% of the 978 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. THRX: 10.56 )
THRX' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 17.1
Current: 10.56

0.17
17.1
Forward Rate of Return (Yacktman) -15.89
THRX's Forward Rate of Return (Yacktman) is ranked higher than
71% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: -10.76 vs. THRX: -15.89 )
THRX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -8.1   Max: -6.2
Current: -15.89

-8.1
-6.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:HVE.Germany
Theravance Inc., was incorporated in Delaware in November 1996 under the name Advanced Medicine, Inc, and began operations in May 1997. The Company changed its name to Theravance, Inc. in April 2002. It is a biopharmaceutical company with a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical. The Company has determined that it operates in a single segment which is the discovery (research), development and commercialization of human therapeutics including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. Its key programs include: RELVAR or BREO (fluticasone furoate/vilanterol), ANORO (umeclidinium bromide/vilanterol) and MABA (Bifunctional Muscarinic Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc (GSK), and its oral Peripheral Mu Opioid. Its drug discovery efforts are based on the principles of multivalency. Multivalency involves the simultaneous attachment of a single molecule to multiple binding sites on one or more biological targets. The Company has applied its expertise in multivalency to discover product candidates and compounds in therapeutic areas. It has conducted research in both relevant laboratory and animal models to demonstrate that by applying the design principles of multivalency. Alhough it has limited in-house active pharmaceutical ingredient (API) production capabilities, the company relies on a number of third parties, including contract manufacturing organizations and its collaborative partners, to produce active pharmaceutical ingredient and drug product. As of December 31, 2012, the company owned 329 issued United States patents and 1,110 granted foreign patents. It competes with number of existing antibacterials manufactured and marketed by major pharmaceutical companies and others. The Company's product candidates are subject to regulation by governmental authorities in the United States and other countries.
» More Articles for THRX

Headlines

Articles On GuruFocus.com
Seth Klarman Buys Cheniere Energy, Keryx Biopharmaceuticals, Idenix Pharmaceuticals, Sells BP, Fidel May 15 2014 
Seth Klarman Buys Micron Technology, Theravance, PBF Energy, Sells BP, AIG, Yamana Gold Nov 13 2013 
Seth Klarman's Top 5 Second Quarter Holdings Aug 14 2013 
Top Four from Baupost’s Seth Klarman Jul 18 2013 
What Can We Earn If We Invest in the Top Five Holdings of the Baupost Group? May 29 2013 
Weekly CEO Sells Highlight: Texas Roadhouse Inc., Theravance Inc., AmerisourceBergen Corp. and Nuanc May 06 2013 
WEEKLY CFO SELLS HIGHLIGHT: THRX, BERY, IPG, PG, ZNGA, TSS May 05 2013 
Weekly Guru Bargains Highlights: PANL, THRX, ZNGA, LORL, AMRN Jan 07 2013 
Weekly CFO Sells Highlight: CMCSA, ACTU, FRGI, PETM, THRX, DXPE, CRZO Jun 04 2012 
sk adding May 12 2012 

More From Other Websites
THERAVANCE INC Files SEC form 8-K, Change in Directors or Principal Officers Sep 19 2014
THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure Sep 18 2014
THERAVANCE INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 08 2014
THERAVANCE INC Files SEC form 8-K, Other Events Sep 04 2014
Drug M&A Boom Driven By Long-Term Trends: PwC Sep 03 2014
THERAVANCE INC Files SEC form 8-K, Regulation FD Disclosure Sep 02 2014
Strong On High Relative Volume: Theravance (THRX) Aug 26 2014
Why the Baupost Group starts new position in Theravance Biopharma Aug 25 2014
THERAVANCE INC Files SEC form 8-K, Change in Directors or Principal Officers Aug 22 2014
Theravance to Present at the Baird 2014 Health Care Conference Aug 21 2014
THERAVANCE INC Financials Aug 15 2014
Theravance (THRX) Incurs Narrower-than-Expected Loss in Q2 Aug 08 2014
THERAVANCE INC Files SEC form 10-Q, Quarterly Report Aug 07 2014
THERAVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition Aug 06 2014
Theravance Reports Second Quarter 2014 Financial Results Aug 06 2014
Theravance, Inc. Appoints Michael W. Aguiar as President and Chief Executive Officer Aug 06 2014
Q2 2014 THERAVANCE INC Earnings Release - After Market Close Aug 06 2014
Theravance to Report Second Quarter 2014 Financial Results on August 6, 2014 Jul 29 2014
[$$] At Theravance, It's Hard to Breathe Easy Jul 25 2014
Theravance (THRX) Is in Oversold Territory: What's Next? Jul 25 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK